Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer. (IXOGoo1)

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by AHS Cancer Control Alberta
Sponsor:
Collaborator:
Sanofi
Information provided by (Responsible Party):
AHS Cancer Control Alberta
ClinicalTrials.gov Identifier:
NCT01129310
First received: May 21, 2010
Last updated: October 2, 2014
Last verified: October 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: July 2015
  Estimated Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)